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ABSTRACT: “Panchakavvyam”, an indigenous preparation, has been referred to in ancient 
vedic literature of India, as having anticarcinogenic influence to the system, suffering from 
cancer.  The levels of the marker enzymes such as lactate dehydrogenase and alkaline 
phospeatase in serum and glycoprotein levels in plasma are analysed.  They are significantly 
reduced in the drug treated group, suggesting that this drug may have anticarcinogenic 
properties.  Histopathological observations made on the tumor tissue of the drug-treated animals 
and the untreated ones, attribute concrete evidence to our inference, explaining more clearly, the 
observations made on the enzyme levels. 
 
INTRODUCTION 
 
Cancer is a dreaded disease, in which a 
group of cells divide progressively in a 
malignant manner, without homeostatic 
control (Luis, 1978).  Fibrosarcoma is a 
malignant, connective tissue tumour (Boyd. 
1964).  Due to fibrosarcoma, approximately 
1600 deaths are reported in U.S. (NIH 
Report).  In chronic stage, it leads to 
cachexia in rats and decreases in survival 
rate of the tomour bearing animals 
(Symington – Carter, 1978). 
 
Not even a single agent, has been proved to 
be promising totally, in the treatment of any 
type of cancer till date with tolerable side 
effects (Marion D. Cridlan, 1978).  The 
indigenous drug “Panchakavvyam”, that is 
used as a sacred combination in some of the 
rituals of Hindu ceremonies in the Southern 
Parts of India (Yajur Vedhika). 
 
The aim of this paper  is to study the 
advantageous effects of the drug, 
“Panchakavvyam”, rendered to the system 
suffering from fibrosarcoma in fighting 
against the malignancy.  In interpreting the 
results of these animal experiments, one 
should be mindful of the fact that this drug 
is having anticarinogenic properties. 
 
MATERIALS AND METHODS 
Animals: 
 
The adult, Wistar strain, male, albino rats, 
obtained from the King, Institute of 
Preventive Medicine, Madras, India, were 
used.  The rats, weighing between 95 – 
105g, initially, were housed six per cage and 
maintained on standard pellet diet 
(Hindustan Lever Ltd., India).  Food and 
water were given ad libitum.  No special 
arrangements were made for the Pages  172 - 179 
 
maintenance of temperature and light, so 
that the animals had a natural environment. 
 
Tomour Induction: 
 
Fibrosarcoma cell line, (20-methyl 
cholanthrene-induced) maintained in 8 – 10 
weeks old, Wistar, male rats, by regular 
passage of 10
6  cells, subcutaneously, was 
used.  1.0 ml of 10 per cent cell suspension, 
containing the same number of cells are 
mentioned above in physiological saline, 
injected into the axillary region, used a 16 
gauge, sterile needle.  The transplanted 
tumour becomes palpable after one week. 
(Krishnaswamy and Purushothaman, 1980). 
 
The drug: 
 
The drug Panchakavvayam was prepared, by 
mixing five products from a cow, as 
described in Smirithikal Vakkiam (Yajur 
Vedhika).  The drug was stored at 4
0C.  in a 
sterile vessel throughout the experimental 
period. 5.0 ml of the drug was given orally, 
for forty days, from the 9
th  day of 
transplantation, using a mouth tube, as a 
single dose.  Care was taken to ingest the 
drug totally without any loss due to emetic 
reactions. 
 
Protein was estimated according to the 
method of Lowry et al  (1951).  Lactate 
dehydrogenase was estimated by the method 
of King (1965).  Alkaline phosphatase was 
estimated by the method of Moog (1946) 
Gamma glytamyl transpeptidase was 
estimated according to the method of 
Orlowski and Meister (1965) and modified 
by  Rosalki and Rau (1972).  Hexose was 
estimated by the method of Wagner (1979) 
and Sialic acid by the method of Warren 
(1959). 
 
Experimental set up: 
 
The rats were divided into 3 groups 
 
Group I Control animals 
 
Group II Animals transplanted with the 
Fibrosarcoma cell line i.e. suffering from the 
developed disease. 
 
Group III Animals transplanted with the 
Fibrosarcoma cell line and which received 
Panchakavvyam. 
 
After forty days of drug  administration 
daily, the animals were sacrificed and the 
above-mentioned  parameters were 
estimated. 
 
For all the statistical evaluations, “students 
T test” was employed. 
 
Histopathology 
 
The tumour tissue pieces were removed by 
excision and were fixed in formal – saline.  
The tissues were processed, Paraffin 
sections obtained and stained with 
Haematoxylin – Eosin by the conventional 
methods. 
 
Results and Discussion 
 
The rapid increase in the turnover of 
malignant cells modulate the enzyme levels 
in blood circulation.  Enzymatic changes 
reflect the overall changes in metabolism, 
that occur during malignancy (Greengard, 
et. al., 1982).  The presence of cancer may 
induce the release of enzymes from the 
surrounding normal tissue (Tietz. 1980). 
 
Table 1 shows the levels of the enzymes 
such as lactate dehydrogenase, alkaline 
phosphatase and Gamma-glutamyl 
transpeptidase in serum. 
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When the level of the enzyme lactate 
dehydrogenase in control animals (Group I ) 
are compared with the tumour bearing 
animals (Group I) the enzyme is 
significantly increased (P<0.001) in the 
tumour bearing group (Group II).  When the 
tumour bearing rats (Group II), are 
compared the drug administered group 
(Group III) there is a significant decrease 
(p<0.01) in the level of the enzyme in the 
drug treated group (Group III). 
 
Lactate dehydrogenase has been recognized 
as a potential tumour marker (Hill, 1957).   
Lactate dehydrogenase has been found to 
correlate well tumour mass and prognosis, in 
a variety of solid tumours including sarcoma 
(Tafafumi and Toshio Kitagawa, 1985).  It 
has been reported that the change in lactate 
dehydrogenase level is more sensitive to the 
effect of the treatment (Ridgway, et al 
1981). 
 
TABLE 1 
 
Serum Lactate dehydrogenase, alkaline phosphatase and Gamma –  Glutamyl 
transpeptidase levels both in control and experimental groups at the end  of the 
experimental period.  Values are expressed (Mean ± S.D).  The activity of the enzymes is 
expressed as mc. Moles of the product liberating | mg of protein | hour. 
(n = 6 animals in each group) 
 
 
Enzymes  Group I  Group II  Group III 
Lactate dehydrogenase 
 
Alkaline Phosphatase  
 
Gamma  –  glutamyl 
transpeptidase 
890.4 ± 75 
 
180.1 ± 18.1 
 
1.71 ± 0.18 
1500 *** ± 110 
 
250.5*** ± 21.9 
 
2.02 ± 0.23 
1250 *** ± 95 
 
214.11* ± 18.34 
 
1.99 
N.S ± 0.22 
 
 
For statistical evaluation of significant variations, Group I is compared with Group II and Group 
III is compared with Group III.  Statistical significant alterations are expressed as 
 
* p<0.05               **p<0.01                ***p<0.001                    N.S. Not Significant 
 
In cachexia glucose is catabolised mainly 
via Embden Meyerhoff pathway, increasing 
the turnover of blood lactate, leading to 
lactic acidosis (Holroyde and Reichard, 
1981).  It may be due to the fact that the 
augmented activity of the enzyme in serum 
as in the untreated animals (Group II) is 
observed.  When the drug which is rich in 
fat is added, it may slowly reverse the 
adverse effects of cachexia by 
supplementing its fat in the place of glucose, 
thus reducing the level of the enzyme as in 
the drug treated (Group III) animals (Tisdal, 
et al 1987). 
 
From the Table. I, the levels of the enzyme 
alkaline phosphatase is inferred.  Alkaline 
phosphatase is a membrane bound enzyme.  
If there is rupture of membrane, then it will 
result in the leakage of the enzyme into the 
circulation, leading to an increase of that 
enzyme (Hilf, et al., 1982).  Similar picture 
is posed i.e the level of alkaline phosphatase 
is increased in the tumour significant Pages  172 - 179 
 
decrease (p<0.05) in the levels of the 
enzyme in the drug treated group (Group III) 
may be interpreted as follows.  Some repair 
mechanism might have been slowly 
triggered in the system, posing a check in 
the rate of the cell destruction, and healing 
the ulceration. 
 
Table 2 shows the levels of glycol-proteins 
such as hexose, hexosamine and sialic acid 
in plasma.  Plasma glycoproteins are the 
potential tumour markers (Dacremount, 
1972).  When the cells undergo neoplastic 
transformations, it not only disrupts its cell 
wall, but also the nearby normal cells, which 
in turn show a clear view in the nature and 
management of the disease (Kapeller, 1976). 
 
 
TABLE 2 
 
Plasma Glycoprotein levels both in control and experimental groups at the end of the 
experimental period.  Values are expressed as Mean ± S.D in mc.g | dl of plasma.  
(n = 6 animals in each group) 
 
Glycoproteins  Group I  Group II  Group III 
Hexose 
Hexosamine 
Sialic acid 
191.33 ± 15.04 
126.6 ± 15.95 
110.1 ± 11.4 
281.16 *** ± 20.76 
195.25 *** ± 14.36 
210.4*** ± 15.9 
250.81* ± 19.5 
174.81* ± 11.67 
180.9** ± 13.3 
 
For statistical evaluation of significant variations, Group I is compared with Group II and Group 
II is compared with Group III.  Statistical alterations are expressed as 
 
* p<0.05                         ** p<0.01                                *** p<0.001 
 
When the untreated group (Group II) is 
compared with the control ones (Group I), 
there is significant increase (p<0.001) in the 
level of the glycoproteins in the untreated 
group (Group II).  When the drug treated 
ones (Group III) are compared with the 
untreated ones (Group II), there is a 
significant decrease (p<0.05) in the level of 
the glycoproteins in the drug treated group 
(Group III).  Sialic acid is much 
significantly reduced (p<0.001) in the drug 
treated group (Group III). 
 
The levels of the glycoproteins correlate 
well correspondingly with the tumour 
burden (Silver et al., 1979).  From the table 
it leads us to hypothesise that the drug 
brings back normophysiology of the affected 
cells from their altered pathophysiology. 
 
Histopathology 
 
Fig. A shows the histopathological changes 
in the tumour tissue of the untreated group 
(Group II).  It has spindle shaped cells with 
hypochromatic nucleus, amphophilic 
cytoplasm with increased mitotic activity. 
 
Fig. B and C show  the different regions of 
the drug administered tumour tissue (Group 
III).  The picture shows marked regenerative 
changes in the drug treated ones (Group III) 
when compared with the untreated ones 
(Group II). 
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